Proteomics Approach Identifies Factors Associated With the Response to Low-Density Lipoprotein Apheresis Therapy in Patients With Steroid-Resistant Nephrotic Syndrome

Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Emiko Kuribayashi-OkumaShunya Uchida

Abstract

Low-density lipoprotein apheresis (LDL-A) has been shown to reduce proteinuria in a subgroup of nephrotic syndrome patients refractory to immunosuppressive therapy. Factors influencing the efficacy of LDL-A in nephrotic syndrome are completely unknown. Using a proteomics approach, we aimed to identify biological markers that predict the response to LDL-A in patients with steroid-resistant nephrotic syndrome (SRNS). Identification of plasma proteins bound to the dextran-sulfate column at the first session of LDL-A was determined by mass spectrometry. To investigate biological factors associated with the response to LDL-A, we compared profiles of column-bound proteins between responders (defined by more than 50% reduction of proteinuria after the treatment) and non-responders by 2-dimensional gel electrophoresis (2-DE) coupled to mass spectrometry in seven patients with SRNS. Evaluation of proteins adsorbed to LDL-A column in patients with SRNS revealed the identity of 62 proteins, which included apolipoproteins, complement components, and serum amyloid P-component (SAP). Comparative analysis of the column-bound proteins between responders and non-responders by 2-DE demonstrated that apolipoprotein E (APOE) and SAP levels were in...Continue Reading

References

Feb 1, 1989·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·T SaitoH Sakaguchi
May 1, 1997·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·C FaucherL Dupouet
Mar 8, 2000·Thrombosis Research·B PalumboH Sinzinger
Nov 27, 2001·Nephron·E MusoUNKNOWN Kansai FGS LDL Apheresis Treatment (K-FLAT) Study Group
Jun 21, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Władysław Sułowicz, Tomasz Stompór
Feb 24, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Ramin SamAshok K Singh
Sep 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Darrell PillingRichard H Gomer
Feb 7, 2008·The Cochrane Database of Systematic Reviews·S C PalmerG F Strippoli
Apr 10, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hassan DihaziGerhard A Mueller
Apr 11, 2008·Contributions to Nephrology·Avram Z Traum, Asher D Schachter
Jul 23, 2008·The Cochrane Database of Systematic Reviews·Norbert BraunNarelle S Willis
Jan 13, 2010·British Journal of Haematology·Julian D GillmoreMark B Pepys
Apr 7, 2010·Science Translational Medicine·Ana P CastañoJeremy S Duffield
Mar 31, 2012·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Hitomi MiyataEri Muso
Dec 18, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Maciej LechHans-Joachim Anders
Feb 16, 2013·Clinical Journal of the American Society of Nephrology : CJASN·Sanjeev SethiSamih H Nasr
Jul 23, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Laurence BeckMeryl Waldman
Feb 7, 2014·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Yumiko YuasaMariko Harada-Shiba
Feb 19, 2014·Clinical and Experimental Nephrology·Eri Muso
Nov 18, 2014·Proteomics. Clinical Applications·Georgia ArentzPeter Hoffmann
Dec 4, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Cheuk-Chun SzetoPhilip Kam-Tao Li

❮ Previous
Next ❯

Citations

Oct 28, 2019·Nature Reviews. Nephrology·Moin A Saleem

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.